Researchers have revealed new details about the CRISPR-Cas5-HNH/Cascade complex, a variant of the type I-E CRISPR-Cas system, ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

Fintel reports that on February 14, 2025, Evercore ISI Group upgraded their outlook for CRISPR Therapeutics (NasdaqGM:CRSP) ...

Biomedical engineers at Duke University have demonstrated a promising new approach that could be used to treat a rare and ...

A study published in Nature Communications and conducted by researchers from the Institute of Physics of the Chinese Academy of Sciences revealed new ...

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by Barclays from $55.00 to $56.00 in a note ...

The CRISPR-Cas9 system offers groundbreaking genome editing capabilities, yet off-target cleavage raises concerns about ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Researchers developed an epigenetic editing approach to silence the PCSK9 gene, achieving long-term cholesterol reduction ...

By treating DNA as a language, Brian Hie’s “ChatGPT for genomes” could pick up patterns that humans can’t see, accelerating ...

Applied DNA Sciences Inc (APDN) reports increased revenues and strategic shifts, while addressing financial hurdles and ...